"These studies proved for the first time that hyponatremia, which is associated with poor outcomes, can be treated effectively with an oral drug that has no significant side effects," said Mihai Gheorghiade, M.D., professor of medicine at Northwestern University's Feinberg School of Medicine, who presented the results of the studies at the AHA meeting.
Hyponatremia is a relatively common electrolyte disorder. It affects a wide spectrum of patients including those with liver problems, heart failure and the elderly. It also may affect marathon runners.
Occurring in 15 to 20 percent of hospitalized patients with heart failure, hyponatremia is the opposite of dehydration. Known as "water intoxication," the condition occurs when serum sodium concentration in the blood falls to dangerously low levels causing cells in the body to stop excreting water. Normal serum sodium levels are between 135 and 145 millimoles per liter (mmol/L). Hyponatremia occurs when serum concentration drops to less than 135 mmol/L. In severe cases, it can lead to cerebral edema and even death.
Yet current therapies for hyponatremia are often ineffective and poorly tolerated. The two SALT studies will be published in the November 16 issue of the New England Journal of Medicine and presented at the AHA meeting offer promising information.
Robert Schrier, M.D., professor of medicine of the University of Colorado, Denver, and Gheorghiade and their colleagues at other institutions, found that tolvaptan, a V2-receptor antagonist developed by Otsuka Pharmaceutical Co., Ltd. and Otsuka Maryland Research Institute, Inc., began to improve patients' serum sodium levels almost immediately.
"This easy-to-administer oral drug begins to normalize serum sodium within hours. The normalization is sustained during long-term therapy," Dr. Gheorghiade said. "It is also important to note that tolvaptan was associated with an improvement in mental performance. This is important since cognition can decrease as a result of low serum sodium."
The SALT-1 and SALT-2 studies (Sodium Assessment with Increasing Levels of Tolvaptan) looked at 443 patients in the U.S. and several international sites. During the trial, about half the patients were put on the tolvaptan regimen, the other half on placebo. In both studies, patients assigned to tolvaptan had higher serum sodium concentrations at day 4 and day 30 than those in the placebo group. During the week after discontinuing the tolvaptan, hyponatremia recurred in patients.
SALT-1 and SALT-2 were identical prospective, multicenter, randomized, double-blind placebo-controlled efficacy studies. SALT-1 was conducted at 42 sites in the U.S., SALT-2 at 50 international sites.
Marla Paul | EurekAlert!
Study relating to materials testing Detecting damages in non-magnetic steel through magnetism
23.07.2018 | Technische Universität Kaiserslautern
Innovative genetic tests for children with developmental disorders and epilepsy
11.07.2018 | Christian-Albrechts-Universität zu Kiel
Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...
Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.
When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.
Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...
Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur
What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...
08.08.2018 | Event News
27.07.2018 | Event News
25.07.2018 | Event News
15.08.2018 | Physics and Astronomy
15.08.2018 | Earth Sciences
15.08.2018 | Physics and Astronomy